利福喷丁与利福平治疗肺结核的疗效与安全性观察

Efficacy and Safety Observation on the Treatment of Tuberculosis with Rifapentine and Rifampicin

目的 分析对比利福喷丁与利福平治疗肺结核的疗效与安全性。方法 选择2015年1月~2016年1月期间我院收治的患者86例,以随机数字表法将其分为研究组与对照组。在常规治疗的基础上,对照组应用利福平治疗,研究组应用利福喷丁治疗。结果 在治疗总有效率比较中,研究组93.02%显著高于对照组74.42%（P〈0.05）。研究组治疗期间的不良反应发生率为13.95%,低于对照组32.56%（P〈0.05）。结论 利福喷丁治疗肺结核的疗效与安全性均优于利福平,适于临床推广。

Objective To analyze the efficacy and safety of rifapentine and rifampicin for the treatment of tuberculosis.Methods 86 cases were selected from January 2015 to January 2015 in our hospital, according to the random number table, they were divided into the study group and the control group. On the basis of routine therapy, the control group given rifampicin treatment, the study group given rifapentine treatment. Results The total effective rate in the treatment of comparison, the study group（93.02%） was significantly higher than the control group（74.42%） （P〈0.05）. The incidence of adverse reactions in the study group during the treatment（13.95%） was lower than the control group（32.56%） （P〈0.05）. Conclusion The curative effect and security of the tuberculosis treated with rifapentine is superior to rifampicin, suitable for clinical promotion.